Latest Commercialisation News

BCI Minerals confirms the Mardie Salt and Potash Project remains on track for first salt shipment in the second half of 2026, supported by binding offtake agreements and a positive salt price outlook driven by supply shortfalls in Asia.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

Ark Mines Limited has secured a crucial mining licence for its Sandy Mitchell Rare Earths Project in North Queensland, marking a key step toward development and commercialisation.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.

Elixir Energy has marked a pivotal step in developing Queensland’s Taroom Trough gas resource with the successful drilling of the Lorelle-3 well and ambitious appraisal plans set for 2026. Positioned near key infrastructure and backed by major players, the company is poised to accelerate commercialisation efforts in this emerging energy hub.

BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.

Renascor Resources has completed construction of its Purified Spherical Graphite demonstration facility in Adelaide, marking a pivotal step towards commercialising its innovative HF-free purification process for battery anode materials.

Green360 Technologies has landed a $3 million federal grant to advance Eco-Clay, a low-carbon cement alternative, aiming to decarbonise Australia's construction sector.

Telix Pharmaceuticals has resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara®), aiming to advance a novel PET imaging agent for glioma diagnosis. The resubmission addresses prior regulatory concerns with additional data, reinforcing hopes for expedited approval.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.